Icon PLC ICLR shares ended the last trading session 3.3% higher at $289.81. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Icon Plc and Medpace are both CROs, but Icon focuses on large pharma with an aggressive M&A strategy, unlike Medpace's small biotech focus. Initially impressed by Icon's financials, we purchased ...

Icon PLC (ICLR) came out with quarterly earnings of $3.35 per share, missing the Zacks Consensus Estimate of $3.85 per share. This compares to earnings of $3.30 per share a year ago. These figures ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry ...

Shares of ICON Public Limited Company (NASDAQ:ICLR) reached a two-month high on Tuesday after RBC Capital Markets launched its coverage with an Outperform recommendation and a $263 target ...

DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported first-quarter earnings of $154.2 million. The Dublin 18, Ireland-based company said it had profit of $1.90 per share. Earnings ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from ...